Tanzania Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2356111
  • December 2012
  • Region: Tanzania
  • 39 pages
  • Business Monitor International
1 of 3

BMI View: We are encouraged by the fact that the Tanzanian government has placed a greater emphasis on development expenditure, highlighting healthcare as a key area of investment, particularly as the country's disease burden is set to increase. However, we are concerned by the continued reliance on foreign grants and concessional loans.

Headline Expenditure Projections

- Pharmaceuticals: TZS340.1bn (US$214mn) in 2011 to an expected TZS406.0bn
(US$257mn) in 2012; +19.4% growth in local currency terms and +19.8% in US dollar terms.

- Healthcare: TZS1,792.12bn (US$1.13bn) in 2011 to TZS2,0549.75bn (US$1.30bn) in 2012; 14.4% growth in local currency terms and 14.7% in US dollar terms.

Risk/Reward Rating:

In BMI's Q113 Risk/Reward Ratings, Tanzania is ranked 19th in the MEA region,
above Gabon and below Namibia and Ghana. A sizeable counterfeiting industry, poor healthcare funding,
corruption, regulatory environment deficiencies and a number of other issues will conspire to keep Tanzania in a similarly lowly position in the MEA matrix. Nevertheless, in comparison with many other African markets (most of which are not surveyed by BMI), Tanzania READ MORE >

Note: Product cover images may vary from those shown
2 of 3

BMI Industry View 5

Pharmaceuticals Risk/Reward Ratings 7
Table: MEA Pharmaceuticals And Healthcare Risk/Reward Ratings, Q113 7

Rewards 9

Risks 9

Tanzania - Market Summary 10

Regulatory Regime 11

Intellectual Property Issues 11

Medicine Procurement 12

Industry Trends And Developments 16

Epidemiology 16

Industry Forecast Scenario 18

Pharmaceuticals Market Forecast 18
Table: Pharmaceuticals Sales Indicators 2008-2016 19

Healthcare Market Forecast 20
Table: Healthcare Expenditure Indicators, 2008-2016 21
Table: Healthcare Governmental Indicators, 2008-2016 22
Table: Healthcare Private Indicators, 2008-2016 22

Macroeconomic Outlook 23
Table: Tanzania - Economic Activity 26

Competitive Landscape 27

Local Production 27

Opportunities In Government Financed And Donor Funded Healthcare Sector 27

Demographic Outlook 29
Table: Tanzania's Population By Age Group, 1990-2020 ('000) 30
Table: Tanzania's Population By Age Group, 1990-2020 (% of total) 31
Table: Tanzania's Key Population Ratios, 1990-2020 32
Table: Tanzania's Rural And Urban Population, 1990-2020 32

Glossary 33

BMI Methodology 35

How We Generate Our Pharmaceuticals Industry Forecasts 35

Pharmaceuticals Risk/Reward Ratings Methodology 36

Ratings Overview 36
Table: Pharmaceuticals Business Environment Indicators 37

Weighting 38
Table: Weighting Of Components 38

Sources 38

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.